ArticleBiomedical optics express2024
Multimodal photoacoustic microscopy and optical coherence tomography ocular biomarker imaging in Alzheimer's disease in mice.
Article in Biomedical optics express, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tracer Techniques in Ophthalmology: Ocular Applications and Systemic Connections.Diagnostics (Basel, Switzerland) · 2026Review
- Gas vesicle-expressing human pluripotent stem cells enable multimodal ultrasound and optical coherence tomographic imaging.BMC biotechnology · 2026Article
- Multi-parametric longitudinal imaging of cerebral biomarkers in a rodent model of Alzheimer's disease.Photoacoustics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease characterized by amyloid beta (Aβ)-containing extracellular plaques and tau-containing intracellular neurofibrillary tangles. Reliable and more accessible biomarkers along with associated imaging methods are essential for early diagnosis and to develop effective therapeutic interventions. Described here is an integrated photoacoustic microscopy (PAM) and optical coherence tomography (OCT) dual-modality imaging system for multiple ocular biomarker imaging in an AD mouse model. Anti-Aβ-conjugated Au nanochains (AuNCs) were engineered and administered to the mice to provide molecular contrast of Aβ. The retinal vasculature structure and Aβ deposition in AD mice and wild-type (WT) mice were imaged simultaneously by dual-wavelength PAM. OCT distinguished significant differences in retinal layer thickness between AD and WT animals. With the unique ability of imaging the multiple ocular biomarkers via a coaxial multimodality imaging system, the proposed system provides a new tool for investigating the progression of AD in animal models, which could contribute to preclinical studies of AD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.